Holly Peay's Blog – June 2013 Archive (1)
Benefit/Risk Survey Results to Be Submitted to FDA
Earlier this week, PPMD hosted a webinar to discuss our FDA “aggressive collaboration” approach and the results from our recent benefit/risk survey. We conducted a rigorous survey of more than 100 parents whose children have Duchenne, gathering invaluable perspectives as to treatment priorities and risk threshold based on realistic but hypothetical treatments – information that PPMD is encouraging regulators to use to…
ContinueAdded by Holly Peay on June 14, 2013 at 10:00am — No Comments
Latest Blog Posts
- PPMD’s Benefit/Risk work highlighted in groundbreaking reports
- FDA Acknowledges the Importance of Benefit-Risk Preferences: Why this Matters to Duchenne
- PPMD and Santhera Pharmaceuticals Team Up on New Benefit/Risk Study Focused on Pulmonary Therapies
- Let’s improve DuchenneConnect’s informed consent. Give your opinion by September 7th.
- PPMD Benefit/Risk Study Results Published in Clinical Therapeutics
- Simple Actions: Real data can drive change
- DuchenneConnect Receives $970,000 Award
Most Popular Blog Posts
- Promising News from Sarepta on Exon 51 Skipping Trial
- Simple Actions: Real data can drive change
- Clinical Trial Expectations
- Pushing the FDA to Accelerate Treatments
- DuchenneConnect Receives $970,000 Award
- FDA Public Workshop Report – Our Message Is Having an Impact
- FDA Acknowledges the Importance of Benefit-Risk Preferences: Why this Matters to Duchenne
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
